HIV prevention news: Europe

From 2012 to 2016, NAM published a monthly bulletin that covered HIV prevention news and research in Europe, and of relevance to Europe. It aimed to strengthen knowledge of new prevention options and share the latest HIV prevention news and research.

In that period, HIV prevention evolved rapidly, with landmark research developments in new prevention technologies and approaches, including HIV treatment as prevention (TasP), pre-exposure prophylaxis (PrEP), expanded testing programmes and advocacy for proven approaches that remain unprovided, such as syringe and needle exchange and condoms in prisons.

An archive of the bulletin is available in English, Spanish, Portuguese, French and Russian.


Issue #3 - December 2012

  • Real-world evidence of treatment reducing heterosexual transmission
  • Half of HIV-positive gay men don’t believe treatment reduces infectiousness
  • Very high rates of HIV infection among young US gay men
  • Disappearing patients limit the proportion of people with HIV who are non-infectious
  • Sharing drug preparation equipment a potential source of hepatitis C transmission
  • Some women with HIV unaware that HIV treatment can protect their babies
  • Two-thirds of sexually active teenagers born with HIV have unsafe sex
  • Project focus - Introduction of new advocacy strategies on HIV prevention in Armenia
  • Other recent news headlines
  • Editors' picks from other sources
  • AVAC/NAM webinar series
  • New prevention bulletin
  • Acknowledgements

Issue #2 - November 2012

  • Some lubricants damage cells – but may not increase HIV risk
  • Young gay men with HIV worry about disclosure, transmission and prosecution – older ones about confidence
  • Study confirms HIV is largely transmitted by recently infected people
  • Drug users starting HIV therapy take fewer sexual and needle-sharing risks
  • Over-the-counter HIV tests may be feasible
  • More gay men than ever diagnosed in the UK
  • Other recent news headlines
  • Editors’ picks from other sources
  • Announcing the AVAC/NAM Webinar series
  • New prevention bulletin
  • Acknowledgements:

Issue #1 - October 2012

  • What’s happening in PrEP?
  • Methadone maintenance halves HIV risk
  • Viral load no defence in Norway
  • More Africans infected in UK than thought
  • Is treatment as prevention working in France?
  • Scots take up HIV testing
  • Other recent news headlines
  • Editors’ picks from other sources
  • New prevention bulletin
  • Acknowledgements

This project has been supported via a grant from Gilead Sciences Europe Ltd, Merck & Co., Inc. and ViiV Healthcare.

Gilead Sciences Europe Ltd, Merck & Co., Inc. and ViiV Healthcare have provided funding for this project and have had no editorial control over the content of the materials.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.